-
公开(公告)号：US20060137435A1
公开(公告)日：2006-06-29
申请号：US11358986
申请日：2006-02-21
Applicant: Benjamin Sullivan
Inventor： Benjamin Sullivan
IPC: G01N13/04
CPC classification number: G01N13/04
Abstract: Osmolarity measurement of a sample fluid, such as tear film, is achieved by depositing an aliquot-sized sample on a sample receiving substrate. The sample fluid is placed on a sample region of the substrate. Energy is imparted to the sample fluid and energy properties of the fluid can be detected to produce a sample fluid reading that indicates osmolarity of the sample fluid. An aliquot-sized volume can comprise, for example, a volume of no more than 20 microliters (μL). The aliquot-sized sample volume can be quickly and easily obtained, even from dry eye sufferers. The imparted energy can comprise electrical, optical or thermal energy. In the case of electrical energy, the energy property of the sample fluid can comprise electrical conductivity. In the case of optical energy, the energy property can comprise fluorescence. In the case of thermal energy, the measured property can be the freezing point of the sample fluid. The substrate can be packaged into a chip, such as by using semiconductor fabrication techniques. An ex vivo osmolarity sensor system that uses the chip can detect energy from the sample region and can provide an accurate osmolarity measurement without user intervention.
-
32.发明申请公开(公告)号：US20050176029A1
公开(公告)日：2005-08-11
申请号：US10970756
申请日：2004-10-20
Applicant: Michael Heller , Benjamin Sullivan , Sanja Zlatanovic , Sadik Esener , Dietrich Dehlinger
Inventor： Michael Heller , Benjamin Sullivan , Sanja Zlatanovic , Sadik Esener , Dietrich Dehlinger
IPC: C12Q1/68 , G01N20060101 , G01N33/00 , G01N33/53 , G01N33/543 , H01L21/00
CPC classification number: G01N33/54346 , B82Y5/00 , B82Y10/00 , B82Y15/00 , B82Y30/00
Abstract: The present invention relates to nanoscale transduction systems that produce reversible signals to facilitate detection. In one respect, the invention relates to the analysis of molecular binding events using higher order signaling nanoscale constructs, or “nanomachines”, that allow nanostructures to be individually detectable, even in the midst of high background noise. Such systems are particularly useful for improving the performance of rare target detection methods, as well as being generally useful in any field in which sensitivity, discrimination and confidence in detection are important.
Abstract translation: 本发明涉及产生可逆信号以促进检测的纳米尺度转导系统。 在一个方面，本发明涉及使用更高级信号的纳米尺度构建体或“纳米机器”的分子结合事件的分析，即使在高背景噪声中也允许纳米结构单独检测。 这种系统对于改善稀有目标检测方法的性能特别有用，并且在敏感性，鉴别和检测置信度重要的任何领域中通常是有用的。
-
公开(公告)号：US11213566B2
公开(公告)日：2022-01-04
申请号：US13574095
申请日：2011-01-19
Applicant: Edward R. Truitt, III , Benjamin Sullivan , Nicholas Tennison
Inventor： Edward R. Truitt, III , Benjamin Sullivan , Nicholas Tennison
IPC: A61K38/17
Abstract: Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition.
-
公开(公告)号：US08551467B2
公开(公告)日：2013-10-08
申请号：US13539986
申请日：2012-07-02
Applicant: Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
Inventor： Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
CPC classification number: A61K31/715 , A61K38/13 , A61K38/1841 , A61K2300/00
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
-
公开(公告)号：US08506944B2
公开(公告)日：2013-08-13
申请号：US12605024
申请日：2009-10-23
Applicant: Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
Inventor： Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
CPC classification number: A61K31/715 , A61K38/13 , A61K38/1841 , A61K2300/00
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
Abstract translation: 眼用组合物及其使用方法，包括用于治疗眼部边界缺乏，与其相关的症状，或与眼表面相关或导致眼部边界缺陷或用于治疗或护理眼科装置的不期望的状况。 眼用组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或其同种型。 眼用组合物还可包含一种或多种眼科可接受的试剂。
-
Patent Agency Ranking
公开(公告)号：US20110144919A1
公开(公告)日：2011-06-16
申请号：US13031051
申请日：2011-02-18
Applicant: Benjamin Sullivan
Inventor： Benjamin Sullivan
IPC: G01N33/48
CPC classification number: G01N13/04 , B01L3/502715 , B01L2300/0654 , G01N21/6486 , G01N27/07 , G01N27/26 , G01N33/487 , G01N2800/162 , G01N2800/24 , G06F19/24
Abstract: A fluid sample is measured with a tear film measuring system that includes a processing device that receives a sample chip comprising a sample region configured to contain an aliquot volume of sample fluid, the processing device configured to perform analyses of osmolarity and of one or more biomarkers within the sample fluid, wherein the analysis of biomarkers includes normalization of biomarker concentration values.
Abstract translation: 用泪液测量系统测量流体样品，所述泪液膜测量系统包括处理装置，所述处理装置接收包含被配置为容纳等分试样体积的样品流体的样品区域的样品芯片，所述处理装置被配置为进行渗透压的分析和一种或多种生物标志物 在样品流体中，其中生物标志物的分析包括生物标志物浓度值的归一化。
-
37.发明申请Ophthalmic Device, and Method of Use Thereof, for Increasing Ocular Boundary Lubrication 有权眼科装置及其使用方法，用于增加眼部边界润滑公开(公告)号：US20110142908A1
公开(公告)日：2011-06-16
申请号：US12940454
申请日：2010-11-05
Applicant: Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
Inventor： Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
CPC classification number: A61K38/14 , A61K9/0048 , A61K9/0051 , A61K31/568 , A61K31/685 , A61K31/688 , A61K31/715 , A61K31/728 , A61K38/13 , A61K38/17 , A61K38/1709 , A61K38/1841 , A61K45/06 , A61K47/02 , A61K47/24 , A61K2300/00
Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.
Abstract translation: 本发明提供一种眼用装置及其使用方法，用于佩戴眼用透镜以增加眼表面边界润滑的个体。 本发明的装置包括设置在眼科镜片上的眼科镜片和牺牲机构，其中所述牺牲机构包括多个表面结合的受体，例如PRG4，透明质酸和DNA适体，其可逆地结合到包含凝胶的润滑组合物 形成剂，表面活性剂或其组合，有效地抑制或防止透镜表面上的蛋白质和脂质吸附，并减轻剪切应力并减少透镜和需要的个体的眼表面之间的摩擦。
-
公开(公告)号：US20110065127A1
公开(公告)日：2011-03-17
申请号：US12866732
申请日：2009-02-09
Applicant: Michael Heller , Geert W. Schmid-Schoenbein , Roy B. Lefkowitz , Benjamin Sullivan
Inventor： Michael Heller , Geert W. Schmid-Schoenbein , Roy B. Lefkowitz , Benjamin Sullivan
IPC: G01N33/573 , C07K7/06 , C07K7/08 , C07K2/00 , C07H21/00 , C08B37/00 , C07C53/00 , G01N27/447 , B82Y15/00
CPC classification number: G01N33/54386 , C07K5/1008 , C07K7/06 , C07K7/08 , C12Q1/34 , C12Q1/37 , G01N33/53 , G01N33/573
Abstract: Provided herein are methods, kits and compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.
Abstract translation: 本文提供了可用于检测体液样品中降解酶和生物分子的方法，试剂盒和组合物。
-
公开(公告)号：US20100092452A1
公开(公告)日：2010-04-15
申请号：US12605024
申请日：2009-10-23
Applicant: Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
Inventor： Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
CPC classification number: A61K31/715 , A61K38/13 , A61K38/1841 , A61K2300/00
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
Abstract translation: 眼用组合物及其使用方法，包括用于治疗眼部边界缺乏，与其相关的症状，或与眼表面相关或导致眼部边界缺陷或用于治疗或护理眼科装置的不期望的状况。 眼用组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或其同种型。 眼用组合物还可包含一种或多种眼科可接受的试剂。
-
公开(公告)号：US09393285B2
公开(公告)日：2016-07-19
申请号：US12940370
申请日：2010-11-05
Applicant: Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
Inventor： Benjamin Sullivan , Tannin A. Schmidt , David A. Sullivan
IPC: A61K38/00 , C08G16/02 , A61K38/17 , A61K9/00 , A61K31/568 , A61K31/715 , A61K38/13 , A61K38/18 , A61K45/06 , A61K31/728
CPC classification number: A61K38/14 , A61K9/0048 , A61K9/0051 , A61K31/568 , A61K31/685 , A61K31/688 , A61K31/715 , A61K31/728 , A61K38/13 , A61K38/17 , A61K38/1709 , A61K38/1841 , A61K45/06 , A61K47/02 , A61K47/24 , A61K2300/00
Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
Abstract translation: 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界不足，与之相关的症状，或与眼表面相关或导致眼部边界缺陷的不期望状况。 本发明的药物组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或同种型。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。
-
-
-
-
-
-
-
-
-
Search Results
46
records
(took 0.031 seconds)
